Cancer Stem Cells, CD44, and Outcomes Following Chemoradiation in Locally Advanced Cervical Cancer: Results From a Prospective Study

International Journal of Radiation Oncology, Biology, Physics
Supriya ChopraShyam Kishore Shrivastava

Abstract

Although cancer stem cells (CSCs) have been reported across solid tumors, there is a dearth of data regarding CSC and its impact on outcomes of cervical cancer. From October 2013 to December 2015, patients with squamous cancer of the cervix (stage IB2-IVA) were included. Pretreatment and posttreatment biopsy was obtained and immunohistochemistry was performed for SOX-2, OCT-4, Nanog, CD44, and Podoplanin. All patients received concurrent radiation and brachytherapy to an equivalent dose of 80 to 84 Gy to point A with concurrent weekly cisplatin. Correlation of CSC expression was performed with known prognostic factors. The effect of stem cell expression on disease outcomes was tested within multivariate analysis. One hundred fifty patients were included. The median dose to point A was 83 Gy (46-89 Gy) and a median of 4 cycles (range, 0-6 cycles) of chemotherapy was administered. At baseline, moderate to strong immunohistochemical expression of SOX-2, OCT-4, Nanog, CD44, and Podoplanin was observed in 12.8%, 4.8%, 24.4%, 15.5%, and 1.3% of patients, respectively. At median follow-up of 30 months (range, 3-51 months), locoregional and distant relapse was observed in 12.2% and 23.1% of patients, of whom 4.7% had both local and dis...Continue Reading

Citations

Feb 12, 2020·Experimental Biology and Medicine·Gašper GrubelnikNina Zidar
May 30, 2021·Medical Oncology·Jacqueline R LimAnn H Kwan
Aug 29, 2021·Viruses·Yakelin Díaz-TejedaAlejandro García-Carrancá
Aug 27, 2021·Current Oncology·Ioannis A Voutsadakis
Sep 14, 2021·Technology in Cancer Research & Treatment·Xiaohang WangJiaxin Zhang

❮ Previous
Next ❯

Related Concepts